Peptide and compounding law · Updated

Is MOTS-c legal?

MOTS-c is not an FDA-approved drug and is on neither the 503A nor the 503B bulks list. In a memo dated May 11, 2026, FDA staff proposed "not adding MOTS-c (free base) or MOTS-c acetate to the 503A Bulks List." Formerly in 503A Category 2, it now sits in the FDA's "nominated but withdrawn" table, which is not a category. On October 30, 2026, HHS gave notice of a draft policy under which it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians compounding with a peptide in its Appendix A, which named MOTS-c when we read it on hhs.gov on November 2, 2026. That is enforcement discretion, not approval.

MOTS-c on each federal list, as of November 17, 2026
ListMOTS-c's statusList's dateSource
FDA-approved drugsNo match in openFDA's Drugs@FDA data; the FDA says neither form is a component of an approved drug or has a USP or NF monographData updated November 16, 2026; FDA memo of May 11, 2026openFDA; FDA briefing, p. 7
503A bulks list (21 CFR 216.23)Not listed; the list has no peptides84 FR 4710 (February 19, 2019)eCFR
503A Categories 1, 2 and 3In noneUpdated May 14, 2026FDA 503A list
FDA's "nominated but withdrawn" tableListed, as "MOTs-C"Page current as of April 22, 2026FDA safety-risk page
503B bulks list and 503B categoriesNot listed; in no categoryMay 16, 2024; March 21, 2025503B bulks list; 503B category list
HHS draft peptide policy, Appendix ANamed, as we read the hhs.gov policy in a browser on November 2, 2026Notice of October 30, 2026; comments closed November 13, 202691 FR 68526; hhs.gov policy
MOTS-c and federal drug policy: the record (checked on November 17, 2026)
DateWhat happenedSource
March 24, 2021The FDA receives Wells Pharmacy Network's nomination of MOTS-c for the 503A listRegulations.gov
September 29, 2023The FDA places "MOTs-C" in 503A Category 2FDA safety-risk page, archived copy
April 14, 2026Wells withdraws twelve peptide nominations, MOTS-c among themRegulations.gov
April 22, 2026The FDA's safety-risk page, updated that day, lists MOTS-c as "nominated but withdrawn"FDA safety-risk page
May 11, 2026FDA staff memo proposes adding neither form to the 503A listFDA briefing, pp. 5, 34
July 23, 2026The advisory committee is asked to vote on each form; the FDA has posted no minutes or resultsFDA questions; meeting page
October 30, 2026HHS gives notice of its draft peptide policy for 503A compounding91 FR 68526

What the FDA says MOTS-c is

The FDA's 2026 evaluation spells the name out as "Mitochondrial Open Reading Frame of the 12S rRNA-c" and says MOTS-c "is reported to be a peptide consisting of 16 amino acids" (FDA briefing, pp. 6-7). It treats the free base and the acetate as "different BDSs" (bulk drug substances) (p. 7). Its Table 1 gives a UNII code for the free base but "Not available" for the acetate, and for the acetate's CAS number says "CAS number of the free base is used" (p. 9).

The certificate of analysis filed with the one nomination the FDA received "refers to one BDS by name in the title and a different BDS by the CAS number" (p. 10). In our reading, the prescription, the supplier's certificate and any policy relied on should all name the same form.

From Category 2 to the withdrawn table

A 503A pharmacy, compounding for "an identified individual patient based on the receipt of a valid prescription order", may use a bulk ingredient only if it has a USP or NF monograph, is a component of an FDA-approved drug, or is on the 503A bulks list (21 U.S.C. 353a). In the FDA's words, there is no monograph for MOTS-c "or its acetate form, and neither is a component of an FDA-approved drug" (FDA briefing, p. 7), and the list at 21 CFR 216.23 holds no peptide.

Wells Pharmacy Network nominated MOTS-c in 2021. The FDA placed it in 503A Category 2 on September 29, 2023 (archived FDA page), and Wells withdrew the nomination on April 14, 2026. The FDA's safety-risk page, current as of April 22, 2026, now lists "MOTs-C" among substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators", and keeps the FDA's statement that the agency "lacks important information regarding any safety issues raised by MOTs-C, including whether it would cause harm if administered to humans" (FDA safety-risk page).

The withdrawn table is not a category. MOTS-c is in none of the three 503A categories (FDA 503A list, May 14, 2026), and only for Category 1 does the FDA say it "does not intend to take action against a compounder" (FDA 503A page). Unlike ipamorelin, it is in no 503B category either (FDA 503B category list), and outsourcing facilities "have not reported preparing" products containing it from January 2017 to December 2025 (FDA briefing, p. 20). In our reading, neither interim policy gives MOTS-c a route.

The FDA's 2026 evaluation and the July committee vote

Although the nomination had been withdrawn, the FDA evaluated both forms "at its discretion" (FDA briefing, p. 7) and chose to present them to its advisory committee (FDA introduction, p. 5). Its staff reported: "No published studies were found in which non-compounded or compounded drug products containing MOTS-c (free base) or MOTS-c acetate were used in humans" (p. 20). The memo concluded: "Accordingly, we propose not adding MOTS-c (free base) or MOTS-c acetate to the 503A Bulks List" (p. 34).

On July 23, 2026 the Pharmacy Compounding Advisory Committee was asked whether each form should "be placed on the list" (FDA questions). As of November 17, 2026 the FDA had posted no minutes or results on the meeting page. A vote is advice in any case: the 503A list is set by regulation, and our Federal Register search on November 17, 2026 found one document naming MOTS-c, the FDA's April 16, 2026 meeting notice.

What the October 30, 2026 HHS draft means for MOTS-c

HHS, not the FDA, gave notice of a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" (91 FR 68526). HHS says it "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance found in Appendix A", citing "significant interest in the use of these peptides in compounding given the lack of availability of approved products." The notice names no peptide. When we read the policy on hhs.gov in a browser on November 2, 2026, Appendix A, on page 4 of 16, listed six: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. That copy called itself an "interim policy" and had no date or version line.

In our reading, the HHS draft is the only federal statement giving a pharmacy any assurance about MOTS-c, and a limited one. The notice says the policy "is not binding on HHS or the public", that HHS may revisit it "if, among other things, a safety signal or product quality issue arises", and that the FDA's future rulemakings "may propose adding some or all of these peptides" to the 503A list. It does not mention section 503B. Comments closed November 13, 2026 (regulations.gov), and we found no final version in the Federal Register as of November 17, 2026.

Our browser reading of the hhs.gov file on November 2, 2026 recorded conditions including documented oral bioavailability for oral forms (condition 8) and an FDA-cleared syringe as the only co-packaged device (condition 9); the reading on November 16, 2026 counted ten conditions and identity tables in Appendix B, pages 5 to 16. We could not read the current hhs.gov file at the source on November 17, 2026, so this page does not describe Appendix B's entry for MOTS-c. The notice points to the HHS website "to find the most current version of the policy"; read MOTS-c's entry there, with its date, before relying on it.

"Research use only" MOTS-c and NDC numbers

The FDA's briefing reports that a Google search indicated "MOTS-c is marketed on websites alone and in combination with other substances" (p. 20). A "research use only" label does not settle intended use, which "may be shown ... by the circumstances surrounding the distribution of the article" (21 CFR 201.128). Our search of the FDA's warning-letter database on November 17, 2026 (letters posted through November 10, 2026) found none naming MOTS-c; in our reading, that is not a clearance. On August 24, 2026 the FDA told a Cornelius, North Carolina seller, whose products did not include MOTS-c, that despite labeling "for laboratory, research, and analytical use", "evidence obtained from your website establishes that your products are intended to be drugs for human use" (FDA warning letter). The HHS notice says nothing about products sold for research.

Nor does an NDC number settle it. openFDA's NDC data, updated November 16, 2026, show nine MOTS-c listings, each a bulk ingredient and none a finished drug (openFDA); openFDA tells users to "assume all results are unvalidated". Under 21 CFR 207.77(b), "assignment of an NDC does not denote approval of the establishment or the drug", and a representation creating "the impression that a drug is approved or is legally marketable because it ... has been assigned or displays an NDC ... is misleading and constitutes misbranding." More in Research-use-only peptides.

North Carolina and next steps

In North Carolina, the Board of Pharmacy lets a pharmacy dispense a compounded drug "only pursuant to a prescription that is valid", bars offering compounded preparations "to other entities for resale", and requires office-use compounding to "comply with applicable federal law" (21 NCAC 46 .2801). In our reading, HHS's statement does not change those rules, and nothing federal lets a clinic keep MOTS-c as office stock: 503A compounding is for an identified patient, and MOTS-c has no 503B route. If you prescribe, compound or sell MOTS-c, see peptide law for clinics and pharmacies, and compare Is BPC-157 legal?, Is TB-500 legal? and Is ipamorelin legal?

Common questions

Is MOTS-c FDA-approved?

No. The FDA said in May 2026 that neither MOTS-c nor its acetate has a USP or NF monograph or is a component of an approved drug, and openFDA's Drugs@FDA data (updated November 16, 2026) show no match.

Is MOTS-c in FDA Category 1 or Category 2?

Neither, today. The FDA placed it in 503A Category 2 on September 29, 2023. After its only nominator withdrew in April 2026, the FDA listed it in a "nominated but withdrawn" table, which is not a category. It is in no 503B category.

Can a pharmacy compound MOTS-c now?

Not through any route on the FDA's own lists, in our reading. HHS's October 30, 2026 draft says HHS does not intend to take enforcement action against 503A compounding with the peptides in its Appendix A, which named MOTS-c when we read it on hhs.gov on November 2, 2026. The notice says the draft is not binding, and the policy we read sets conditions.

Did the FDA advisory committee approve MOTS-c?

An advisory committee does not approve drugs. On July 23, 2026 it was asked whether each form of MOTS-c should be placed on the 503A list. The FDA had posted no minutes or results as of November 17, 2026, and its staff had proposed against listing.

Can a med spa keep MOTS-c as office stock?

In our reading, no. MOTS-c is not on the 503B bulks list and is in no 503B category, and the HHS draft covers 503A compounding, which is for an identified patient.

Is it legal to buy MOTS-c online as a research peptide?

A "research use only" label does not decide intended use. Our November 17, 2026 search of the FDA's warning-letter database found none naming MOTS-c, but in August 2026 the FDA called a North Carolina seller's "research" peptides, which did not include MOTS-c, unapproved new drugs.

Update log

  • November 17, 2026. Published. Read at the source November 17, 2026: the FDA's MOTS-c briefing (memo of May 11, 2026), introduction and questions for the July 23-24, 2026 committee meeting, the meeting page (August 6, 2026; no minutes), 503A category list (May 14, 2026), 503A page, safety-risk page (April 22, 2026) and an archived copy of it, 503B category list (March 21, 2025) and 503B bulks list; the Federal Register notices 91 FR 20465 and 91 FR 68526 and the regulations.gov records; 21 U.S.C. 353a; 21 CFR 216.23, 201.128 and 207.77; the FDA warning-letter database and an August 24, 2026 letter; openFDA data (November 16, 2026); and 21 NCAC 46 .2801. hhs.gov could not be read by automated tools; Appendix A and the policy's conditions are described as we read them in a browser on November 2 and November 16, 2026, and Appendix B's MOTS-c entry is not described.

Sources

Related

Published November 17, 2026; updated November 17, 2026. General information, not legal advice. See the disclaimer.

Weighing MOTS-c under the HHS draft?

DPS Law advises clinics, physicians and pharmacies on North Carolina and federal compounding law. For another state's pharmacy or medical board rules, talk to a lawyer licensed in that state. Our attorney is licensed in North Carolina only.

Peptide attorney in Charlotte, NC